Sankhala KK - Search Results

1

Heat shock proteins: a potential anticancer target.

Sankhala KK, Mita MM, Mita AC, Takimoto CH. Sankhala KK, et al. Curr Drug Targets. 2011 Dec;12(14):2001-8. doi: 10.2174/138945011798829339. Curr Drug Targets. 2011. PMID: 21777196 Review.

2

Targeting sarcomas: novel biological agents and future perspectives.

Mahalingam D, Mita A, Sankhala K, Swords R, Kelly K, Giles F, Mita MM. Mahalingam D, et al. Curr Drug Targets. 2009 Oct;10(10):937-49. doi: 10.2174/138945009789577990. Curr Drug Targets. 2009. PMID: 19860642 Review.

3

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.

Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. Mita M, et al. Expert Opin Investig Drugs. 2008 Dec;17(12):1947-54. doi: 10.1517/13543780802556485. Expert Opin Investig Drugs. 2008. PMID: 19012509 Review.

4

Targeting the mTOR pathway using deforolimus in cancer therapy.

Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM. Mahalingam D, et al. Future Oncol. 2009 Apr;5(3):291-303. doi: 10.2217/fon.09.9. Future Oncol. 2009. PMID: 19374536 Review.

5

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.

Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. Sankhala K, et al. Target Oncol. 2009 Apr;4(2):135-42. doi: 10.1007/s11523-009-0107-z. Epub 2009 Apr 21. Target Oncol. 2009. PMID: 19381454 Review.

6

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.

Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P. Mita AC, et al. Clin Cancer Res. 2010 Jun 1;16(11):3044-56. doi: 10.1158/1078-0432.CCR-09-3368. Epub 2010 May 25. Clin Cancer Res. 2010. PMID: 20501621 Clinical Trial.

7

Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.

Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M. Tolcher AW, et al. Clin Cancer Res. 2011 Jan 15;17(2):363-71. doi: 10.1158/1078-0432.CCR-10-1411. Epub 2011 Jan 11. Clin Cancer Res. 2011. PMID: 21224368 Clinical Trial.

8

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Vemulapalli S, Mita A, Alvarado Y, Sankhala K, Mita M. Vemulapalli S, et al. Target Oncol. 2011 Mar;6(1):29-39. doi: 10.1007/s11523-011-0179-4. Epub 2011 Apr 28. Target Oncol. 2011. PMID: 21533543 Review.

9

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.

Mahalingam D, Nemunaitis JJ, Malik L, Sarantopoulos J, Weitman S, Sankhala K, Hart J, Kousba A, Gallegos NS, Anderson G, Charles J, Rogers JM, Senzer NN, Mita AC. Mahalingam D, et al. Cancer Chemother Pharmacol. 2014 Dec;74(6):1241-50. doi: 10.1007/s00280-014-2602-x. Epub 2014 Oct 11. Cancer Chemother Pharmacol. 2014. PMID: 25304209 Clinical Trial.

10

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.

Sankhala K, Takimoto CH, Mita AC, Xiong H, Rodón J, Mehrvarz Sarshekeh A, Burns K, Iizuka K, Kopetz S. Sankhala K, et al. Invest New Drugs. 2019 Feb;37(1):76-86. doi: 10.1007/s10637-018-0602-0. Epub 2018 Apr 18. Invest New Drugs. 2019. PMID: 29667134 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page